Drug Trial Radar · NCT06227910
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Jan 2, 2025
Primary completion
Jun 8, 2027
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upadacitinib or vedolizumab and placebo) for 12 weeks. Participants responding to the treatment will then receive vedolizumab only (monotherapy) for an additional 40 weeks. During the study, participants will visit their study clinic 15 times.
Conditions
- Crohn's Disease
Interventions
VedolizumabDrug
Vedolizumab IV infusion.
UpadacitinibDrug
Upadacitinib over-encapsulated tablets.
PlaceboDrug
Upadacitinib matched placebo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Remission Based on the CDAI at Week 12Time frame: Week 12
- Percentage of Participants Exhibiting an Endoscopic Response Based on Simple Endoscopic Score for CD (SES-CD) at Week 12Time frame: Week 12
Locations
138 sites in 26 countries. Site status is shown where the registry gives one.
UCSD Medical Center
La Jolla, California · Not yet recruiting
Keck Medicine Of USC - USC Healthcare Center 1
Los Angeles, California · Not yet recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
GI PROS, Inc.
Naples, Florida · Active not recruiting
Orlando Health Ambulatory Care Center
Orlando, Florida · Active not recruiting
USF Health Morsani Center for Advanced Healthcare
Tampa, Florida · Active not recruiting
Indiana University (IU) Health University Hospital
Indianapolis, Indiana · Active not recruiting
University of Kentucky
Lexington, Kentucky · Active not recruiting
Mount Sinai Hospital - The Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical Center
New York, New York · Active not recruiting
Columbia University Medical Center, New York-Presbyterian Hospital
New York, New York · Not yet recruiting
Lenox Hill Hospital Northwell Health
New York, New York · Active not recruiting
Gastroenterology Associates
Greenville, South Carolina · Active not recruiting
Rapid City Medical Center
Rapid City, South Dakota · Active not recruiting
Southern Star Research Institute, LLC
San Antonio, Texas · Recruiting
Tyler Research Institute, LLC
Tyler, Texas · Recruiting
Virginia Mason Medical Center
Seattle, Washington · Active not recruiting
Swedish Cancer Institute
Seattle, Washington · Not yet recruiting
University of Washington Medical Center - Montlake
Seattle, Washington · Not yet recruiting
Medical College of Wisconsin Cancer Center - Froedtert Hospital
Milwaukee, Wisconsin · Not yet recruiting
Johannes Kepler Universitat Linz (JKU)
Linz, Austria · Not yet recruiting
Landeskrankenhaus Salzburg, Innere Medizin I, Labor im Erdgeschoss
Salzburg, Austria · Not yet recruiting
Krankenhaus der Barmherzigen Brueder Wien
Vienna, Austria · Not yet recruiting
Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) - Universitaetsklinik fuer Innere Medizin III
Vienna, State of Vienna, Austria · Not yet recruiting
Medical University Innsbruck
Innsbruck, Tyrol, Austria · Not yet recruiting
Imelda GI Clinical Research Center
Bonheiden, Belgium · Active not recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Not yet recruiting
University Hospitals Leuven
Leuven, Belgium · Not yet recruiting
Centre Hospitalier Chretien MontLegia
Liège, Belgium · Not yet recruiting
Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Brussel
Brussels, Anderlecht, Belgium · Not yet recruiting
Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF)
Rio de Janeiro, Brazil · Not yet recruiting
Hospital das Clinicas of the University of Sao Paulo (Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC/FMUSP))
São Paulo, Brazil · Not yet recruiting
Unidade de Pesquisa Clinica UPC Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
São Paulo, Brazil · Not yet recruiting
Hospital Universitario Cajuru
Curitiba, Paraná, Brazil · Not yet recruiting
Faculdade de Medicina de Botucatu
Botucatu, São Paulo, Brazil · Not yet recruiting
Centro de Estudos Clinico do Interior Paulista - CECIP
Jaú, São Paulo, Brazil · Not yet recruiting
Pesquisare Saude
Santo André, São Paulo, Brazil · Not yet recruiting
Heritage Medical Research Clinic - University Of Calgary
Calgary, Alberta, Canada · Active not recruiting
University of Manitoba-Winnipeg Regional Health Authority-Health Sciences Centre
Winnipeg, Manitoba, Canada · Not yet recruiting
Dalhousie University
Halifax, Nova Scotia, Canada · Not yet recruiting
Barrie GI Associates
Barrie, Ontario, Canada · Recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.